Arrowhead, Sarepta Skyrocket

Sarepta rebuilds drug pipeline with Arrowhead deal
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity.
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics.
Arrowhead climbs after licensing deal with Sarepta
Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT) for various clinical and preclinical programs.
Arrowhead Pharma, Sarepta TX ink new gene therapy deal
Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, Sarepta will pay Arrowhead $500 million upfront and make a $325 million equity investment to gain access to Arrowhead's gene silencing technologies,
Sarepta deal with Arrowhead a ‘prudent move,’ says Leerink
After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion. Sarepta will secure exclusive global rights to multiple programs for rare genetic diseases affecting muscles,
Business Insider15h
Sarepta Therapeutics: Strategic Expansion and Robust Pipeline Justify Buy Rating and $217 Price Target
Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a ...
GlobalData on MSN10h
Arrowhead and Sarepta link for rare genetic disease treatments
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.C2GW7kSb.js ...
Zacks.com on MSN4h
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short-term ...
Sarepta Therapeutics Receives Buy Rating from Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth Potential
Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...
STAT1d
Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases
Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...
bovnews3h
Sarepta Therapeutics Inc (SRPT) Surge: Analyzing Today’s Price Increase
H.C. Wainwright has recently initiated Sarepta Therapeutics Inc (SRPT) stock to Sell rating, as announced on November 25, 2024, according to Finviz. Earlier, on November 7, 2024, Cantor Fitzgerald had ...
FierceBiotech1d
Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
MM&M6h
Rx Rundown: Roche, Sarepta Therapeutics, Merck and more
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...